| 000 | 01717 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518043033.0 | ||
| 264 | 0 | _c20200825 | |
| 008 | 202008s 0 0 eng d | ||
| 022 | _a1477-092X | ||
| 024 | 7 |
_a10.1177/1078155219851543 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKhalighi, Parisa R | |
| 245 | 0 | 0 |
_aUtilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. _h[electronic resource] |
| 260 |
_bJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners _cApr 2020 |
||
| 300 |
_a529-535 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAcute Kidney Injury _xepidemiology |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGout Suppressants _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperuricemia _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTumor Lysis Syndrome _xdrug therapy |
| 650 | 0 | 4 |
_aUrate Oxidase _xadministration & dosage |
| 650 | 0 | 4 |
_aUric Acid _xmetabolism |
| 700 | 1 | _aMartens, Kylee L | |
| 700 | 1 | _aWhite, Andrew A | |
| 700 | 1 | _aLi, Shan | |
| 700 | 1 | _aSilgard, Emily | |
| 700 | 1 | _aFrieze, Deborah | |
| 700 | 1 | _aGarcia, David A | |
| 700 | 1 | _aLi, Ang | |
| 773 | 0 |
_tJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners _gvol. 26 _gno. 3 _gp. 529-535 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/1078155219851543 _zAvailable from publisher's website |
| 999 |
_c29767604 _d29767604 |
||